• 1
    Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. New Engl J Med 2002; 46: 580590.DOI: 10.1056/NEJMra011295
  • 2
    Bunnapradist S, Daswani A, Takemoto SK. Patterns of administration of antibody induction therapy and their associated outcomes. In: TerasakiPI, CeckaJM, eds. Clinical Transplants 2002, UCLA Tissue Typing Laboratory, 2003: 351358.
  • 3
    Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry for Transplant Recipients: Transplant Data 1992–2001: Department of Health and Human Services Health Resources and Services Administration, Office of Special Programs, Division of Transplantation , Rockville , MD ; United Network for Organ Sharing , Richmond , VA ; University Renal Research and Education Association , Ann Arbor MI , 2002.
  • 4
    Hoffmann SC, Kampen RL, Amur S et al. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia/reperfusion injury. Transplantation 2002; 74: 916923.DOI: 10.1097/00007890-200210150-00003
  • 5
    Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative Campath-1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 17011702.DOI: 10.1016/S0140-6736(98)24023-2
  • 6
    Calne R, Moffatt SD, Friend PJ et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 16131616.
  • 7
    Starzl TE, Murase N, Abu-Elmagd K et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 15021510.DOI: 10.1016/S0140-6736(03)13175-3
  • 8
    Knechtle SJ, Pirsch JD, H Fechner J Jr et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722730.DOI: 10.1034/j.1600-6143.2003.00120.x
  • 9
    Swanson SJ, Hale DA, Mannon RB et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360: 16621664.DOI: 10.1016/S0140-6736(02)11606-0
  • 10
    Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120129.DOI: 10.1097/01.TP.0000071362.99021.D9
  • 11
    Leventhal JR, Gallon L, Kaufman DB. Alemtuzumab (Campath 1-H) facilitates prednisone-free immunosuppression in kidney transplant recipients. Am J Transplant 2003; 3(Suppl. 5): S310.
  • 12
    Knechtle SJ, Vargo D, Fechner J et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 16.DOI: 10.1097/00007890-199701150-00002
  • 13
    Knechtle SJ, Fechner JH Jr, Dong Y et al. Primate renal transplants using immunotoxin. Surgery 1998; 124: 438446.DOI: 10.1067/msy.1998.91184
  • 14
    Thomas JM, Eckhoff DE, Contreras JL et al. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: absence of chronic allograft nephropathy. Transplantation 2000; 69: 24972503.DOI: 10.1097/00007890-200006270-00007
  • 15
    Thomas JM, Hubbard WJ, Sooudi SK, Thomas FT. STEALTH matters: a novel paradigm of durable primate allograft tolerance. Immunol Rev 2001; 183: 223233.DOI: 10.1034/j.1600-065x.2001.1830118.x
  • 16
    Chen Z, Cobbold S, Metcalfe S, Waldmann H. Tolerance in the mouse to major histocompatibility complex-mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8. Eur J Immunol 1992; 22: 805810.
  • 17
    Kirk AD, Hale DA, Cendales LC et al. Results from a Human Tolerance Trial using Alemtuzumab (Campath-1H) with Deoxyspergualin (DSG). Am J Transplant 2003; 3(Suppl. 5): S310.
  • 18
    Fischer H, Gjorloff A, Hedlund G, Hedman H, Lundgren E, Kalland T et al. Stimulation of human naive and memory T helper cells with bacterial superantigen. Naive CD4+45RA+ T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway. J Immunol 1992; 148: 19931998.
  • 19
    Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994; 152: 26752685.
  • 20
    Waldmann H, Cobbold S. Regulating the immune response to transplants. a role for CD4+ regulatory cells? Immunity 2001; 14: 399406.DOI: 10.1016/S1074-7613(01)00120-0
  • 21
    Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708712.DOI: 10.1038/44385
  • 22
    Ibrahim S, Dawson DV, Van Trigt P, Sanfilippo F. Differential infiltration by CD45RO and CD45RA subsets of T cells associated with human heart allograft rejection. Am J Pathol 1999; 142: 17941803.
  • 23
    Chalasani G, Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Recall and propagation of allospecific memory T cells independent of secondary lymphoid organs. Proc Natl Acad Sci U S A 2002; 99: 61756182.
  • 24
    De Rosa SC, Herzenberg LA, Herzenberg LA, Roederer M. 11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity. Nat Med 2001; 7: 245248.DOI: 10.1038/84701
  • 25
    De Rosa SC, Brenchley JM, Roederer M. Beyond six colors: a new era in flow cytometry. Nat Med 2003; 9: 112117.DOI: 10.1038/nm0103-112
  • 26
    Hoffmann SC, Pearl JP, Blair BJ, Kirk AD. Immune profiling: molecular monitoring in renal transplantation. Front Biosci 2003; 8: 444462.
  • 27
    Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 1994; 153: 28072811.
  • 28
    Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995; 42: 455500.
  • 29
    Choi YW, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J. Interaction of Staphylococcus aureus toxin “superantigens” with human T cells. Proc Natl Acad Sci U S A 1989; 86: 89418945.
  • 30
    Bernstein WB, Cox JH, Aronson NE et al. Measurement of immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4+ T cells in HIV. Clin Immunol 2004; 111: 262274.
  • 31
    Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 12981302.DOI: 10.1038/15256
  • 32
    Wells AD, Li XC, Li Y et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 13031307.DOI: 10.1038/15260
  • 33
    Hoffmann SC, Kampen RL, Mannon RB, Kleiner DE, Kirk AD. Molecular and histological characterization of monocyte predominant rejection following Campath-1H rejection. Am J Transplant 2002; 2(Suppl. 3): S378.
  • 34
    Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000; 1: 426432.DOI: 10.1038/80868
  • 35
    Tan JT, Dudl E, LeRoy E et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A 2001; 98: 87328737.DOI: 10.1073/pnas.161126098
  • 36
    Fabian I, Flidel O, Gadish M, Kletter Y, Slavin S, Nagler A. Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils. Exp Hematol 1993; 21: 15221527.
  • 37
    Rowan W, Tite T, Topley P, Brett SJ. Cross-linking of the Campath-1 antigen (CD52) moderates growth inhibition in human B- and T-cell lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998; 95: 427436.DOI: 10.1046/j.1365-2567.1998.00615.x
  • 38
    Wu Z, Bensinger SJ, Zhang J et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10: 8792.DOI: 10.1038/nm965
  • 39
    Dummer W, Niethammer AG, Baccala R et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002; 110: 185192.DOI: 10.1172/JCI200215175
  • 40
    Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002; 2: 417426.
  • 41
    Adams AB, Williams MA, Jones TR et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 18871895.DOI: 10.1172/JCI200317477
  • 42
    Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol 2002; 10: 101108.DOI: 10.1016/S0966-3274(02)00055-2
  • 43
    Wekerle T, Sayegh MH, Ito H et al. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation 1999; 68: 13481355.DOI: 10.1097/00007890-199911150-00022
  • 44
    Seung E, Iwakoshi N, Woda BA et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 2000; 95: 21752182.
  • 45
    Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol 2002; 3: 627634.
  • 46
    Forman D, Welsh RM, Markees TG et al. Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms. J Immunol 2002; 168: 60476056.
  • 47
    Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol 2002; 169: 46674673.